Breast Cancer Clinical Trials in Philadelphia

Showing 181-200 of 608 trials

FDG PET/CT in Breast Cancer Bone Mets

NCT01996046

This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.

Estrogen Receptor Positive Breast CancerBone Metastases

University of Pennsylvania75 participantsStarted Sep 2013

Philadelphia, Pennsylvania, United States

RECRUITING< 1 mile

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+13 more

Guardant Health, Inc.2,020 participantsStarted Sep 2021

Birmingham, Alabama, United States • Chandler, Arizona, United States • Hot Springs, Arkansas, United States +54 more locations

FDG PET/CT in Breast Cancer Bone Mets

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Breast Cancer Trials in Other Cities

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

The Breast Program - Translational Cancer Resource

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

Clinical Significance of Germline BRCA Mutations

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

A Study of ADRX-0706 in Select Advanced Solid Tumors

Other Conditions in Philadelphia